Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Short-term Investments (2024)

Corvus Pharmaceuticals has reported Short-term Investments over the past 1 years, most recently at $43.2 million for Q4 2024.

  • Quarterly results put Short-term Investments at $43.2 million for Q4 2024, changed N/A from a year ago — trailing twelve months through Dec 2024 was $43.2 million (changed N/A YoY), and the annual figure for FY2024 was $43.2 million, changed.
  • Short-term Investments for Q4 2024 was $43.2 million at Corvus Pharmaceuticals.
  • Over the last five years, Short-term Investments for CRVS hit a ceiling of $43.2 million in Q4 2024 and a floor of $43.2 million in Q4 2024.